We show co-occurrence of amplifications in MYC and genes from the PI3K pathway in HGSOC and other CIN-driver tumours and that inhibition of the activated mTOR survival pathway in the context of MYC-amplified tumours should be considered in future clinical trials (Fig. 1). This evidence concerns the gene PIK3CA and neoplasm.